Clinical Trials

Nuvance Health® serves as a research site for clinical trials that explore promising new ways to detect, diagnose, treat and prevent diseases.
researcher handles test tube with tweezers

Fighting Disease Through Innovation

Joining a clinical trial at Nuvance Health is a way to help make real progress against disease. As a clinical trial site, we test promising new therapies for diagnosing and treating many diseases. Highlights of our program include:

  • Access to new treatments: Nuvance Health provides a local site for national and international clinical trials. Eligible patients may have access to promising therapies without traveling far from home.
  • Experience: The clinical research team leads a high volume of studies each year and has more than 40 years of collective experience. Nuvance Health’s clinical research coordinators are certified through the Association of Clinical Research Professionals.
  • Focus on patients: Researchers at Nuvance Health are knowledgeable, careful and thorough. We follow guidelines to protect patients and offer suitable treatment options.
  • High standards: Our internal and external Institutional Review Boards review all clinical trials in depth to keep patients safe and comfortable.

A Range of Clinical Trials

Nuvance Health participates in all phases of clinical trials, from Phase I to Phase IV. We study new screening, prevention, diagnostic and treatment options for:

  • Cancer
  • Cardiology
  • Dermatology
  • Electrophysiology
  • Emergency medicine
  • Endocrinology
  • Gastroenterology
  • General surgery
  • Infectious disease
  • Internal medicine
  • Interventional cardiology
  • Nephrology
  • Oncology
  • Pediatrics
  • Perinatology
  • Psychiatry
  • Pulmonary
  • Rheumatology
  • Wound care

Joining a Clinical Trial at Nuvance Health

The care team talks with you about any clinical trials for which you may be eligible. We explain what to expect from a clinical trial, so you can decide if taking part in one is right for you. 


To inquire if you're eligible for a clinical trial, contact: or call (203) 739-4551.

Clinical Trial Listings

  • Arrhythmia 

    A multicenter, Randomized, Active-control study to evaluate the safety and tolerability of two blinded doses of Abenacimab compared with open label rivaroxaban in patients with Atrial Fibrillation.
    Product Surveillance Registry Platform
    Evaluate the periodic reporting of safety and effectiveness of Medtronic market-released products for their intended use.
    Librexia AF
    A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation.

  • Coronary Disease 

    HP-4/TIMI 65/ORION 4
    A double-blind, randomized, placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.
    Vesalius CV
    A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infactrion or Stroke
    Expand G4
    A Post-Market Study Assessment of the Safety and Performance of the MitraClip G4 System 
    Librexia ACS
    A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

  • Eosinophilic Esophagitis 
    SP-1011-004 EAP
    APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients with Eosinophilic Esophagitis
    Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, followed by a Single-arm Open-label Extension, in Adult Subjects with Eosinophilic Esophagitis 
  • Heart Failure  

    Algorithm using LINQ Sensors for Evaluation and Treatment of Heart Failure (ALLEVIATE-HF)


    This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
    DRAIN-HF trial evaluates a novel treatment for chronic heart failure patients who’ve experienced acute decompensated heart failure (ADHF) and unresponsive to standard care. It involves using the Aortix circulatory support device to aid heart and kidney function. The trial is a prospective, multi‐center, randomized, non‐blinded study to comparing the safety and effectiveness of the Aortix system to standard medical therapy. Patients will be randomly assigned to receive either the Aortix system or standard therapy. The temporary Aortix pump is placed in the decending aorta during hospitalization and will remain for several days, with the duration determined by the clinical team. Patients will be monitored for 30 days post-hospital discharge. The study aims to enroll 268 heart failure patients across 45 clinical sties in the US. 
    The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).

  • Infectious Disease

    Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children

  • Lupus 

    A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without Benlysta (belimumab)
    A Prospective Observational Registry of Patients Treated with LUPKYNIS (voclosporin) in the US

  • Multiple Sclerosis 

    An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies

  • Myocardial Infarction 
    A multi-center randomized post-approval evaluation of the delivery of intracoronary hyperoxemic supersaturated oxygen therapy for 60 minutes in anterior acute myocardial infarction patients with successful reperfusion (VIA PCI) ≤ six hours after symptom onset
    A pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized with Acute Myocardial Infarction 
  • Parkinson's Disease 


    A Double-Blind, Placebo-controlled, Randomized, 18-month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 In Study Participants with Early Parkinson's Disease

  • Pulmonary 

    A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States.
    A phase 2, double-blind, randomized, active-control, parallel group study to assess the pharmacokinetics, pharmacodynamics, immunogenicity, and safety of INBRX-101 compared to plasma derived Alpha 1-proteinase inhibitor (A1PI) augmentation therapy in adults with Alpha-1 Antitrypsin deficiency (AATD) Emphysema
    A phase III, 520week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with chronic obstructive pulmonary disease (COPD) 

  • Stroke 

    Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)
    Oceanic Stroke
    A multicenter, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor Asundexian (BAY 2433334) for the secondary prevention of ischemic stroke in adult patients with an acute non-cardioembolic ischemic stroke or high-risk TIA  

  • Surgery 
    Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery after Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection
    Registry of Myriad Utilization in Soft Tissue Reconstruction Procedures 
  • Vascular 

    A Study of Patients with Lower Extremity Acute Limb Ischemia to Remove Thrombus with the Indigo® Aspiration System